Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Revolution Medicines (RVMD) Interest & Investment Income: 2018-2024

Historic Interest & Investment Income for Revolution Medicines (RVMD) over the last 7 years, with Dec 2024 value amounting to $86.9 million.

  • Revolution Medicines' Interest & Investment Income rose 8.19% to $22.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.6 million, marking a year-over-year increase of 7.08%. This contributed to the annual value of $86.9 million for FY2024, which is 82.98% up from last year.
  • According to the latest figures from FY2024, Revolution Medicines' Interest & Investment Income is $86.9 million, which was up 82.98% from $47.5 million recorded in FY2023.
  • In the past 5 years, Revolution Medicines' Interest & Investment Income ranged from a high of $86.9 million in FY2024 and a low of $929,000 during FY2021.
  • Over the past 3 years, Revolution Medicines' median Interest & Investment Income value was $47.5 million (recorded in 2023), while the average stood at $47.8 million.
  • As far as peak fluctuations go, Revolution Medicines' Interest & Investment Income slumped by 58.49% in 2021, and later spiked by 885.36% in 2022.
  • Over the past 5 years, Revolution Medicines' Interest & Investment Income (Yearly) stood at $2.2 million in 2020, then slumped by 58.49% to $929,000 in 2021, then spiked by 885.36% to $9.2 million in 2022, then soared by 418.70% to $47.5 million in 2023, then skyrocketed by 82.98% to $86.9 million in 2024.